New Cystic Fibrosis-Related Diabetes Biomarkers Emerge – European Medical Journal Cystic Fibrosis-Related Diabetes Biomarkers

New Cystic Fibrosis-Related Diabetes Biomarkers Emerge – European Medical Journal Cystic Fibrosis-Related Diabetes Biomarkers

February 7, 2026 discoverhiddenusacom Health

Detecting diabetes in individuals with cystic fibrosis (CF) can be challenging due to subtle changes in glucose levels. New research suggests that tracking shifts in circulating microRNAs – small molecules that play a role in gene regulation – during an oral glucose tolerance test (OGTT) may offer a more sensitive method for identifying both cystic fibrosis-related diabetes (CFRD) and earlier stages of glucose intolerance.

Signals in the Blood

Cystic fibrosis-related diabetes is the most common complication affecting people with CF. A Danish study involving 93 adults with CF investigated whether the levels of these microRNAs differed based on a person’s glucose tolerance and how quickly those levels changed after consuming glucose.

Did You Know? Researchers tracked microRNA levels at multiple timepoints during an oral glucose tolerance test, rather than relying on a single measurement.

Participants were categorized into four groups: normal glucose tolerance, indeterminate glucose tolerance, impaired glucose tolerance and CFRD. Serum samples were collected during the OGTT, allowing researchers to observe dynamic changes in microRNA levels.

Rapid Shifts Identified

The investigation identified four microRNAs that showed differing levels at the start of the test. Other microRNAs exhibited different response patterns during the OGTT depending on the participant’s glucose tolerance. Specifically, miR-34a-5p and miR-122-5p were found to be elevated in individuals with indeterminate glucose tolerance and CFRD, and these elevations correlated with markers of liver damage.

Another microRNA, miR-223-3p, displayed unique response patterns during the OGTT based on glucose tolerance, suggesting it could help differentiate between metabolic states in CF. Researchers used sequencing and validation to confirm these findings.

Expert Insight: The identification of these microRNAs and their dynamic responses during glucose challenges suggests a potential for more nuanced monitoring of metabolic health in individuals with cystic fibrosis, moving beyond traditional glucose measurements.

Potential for New Diagnostic Tools

To understand how these microRNAs might function, researchers studied their effects on insulin-secreting cells. They found that increasing levels of miR-122-5p and miR-223-3p boosted insulin secretion when glucose was present, while increasing miR-34a-5p reduced cell viability. The authors suggest that these circulating microRNAs could be valuable tools for diagnosing and monitoring CFRD, and may reflect communication between metabolic organs and the pancreas.

Frequently Asked Questions

What is an oral glucose tolerance test?

An oral glucose tolerance test (OGTT) involves measuring blood glucose levels at baseline and at multiple timepoints after a person consumes a sugary drink, allowing assessment of how the body processes glucose.

What are microRNAs?

MicroRNAs are small molecules that regulate gene expression and are found circulating in the blood. Researchers found that shifts in these molecules correlated with glucose tolerance status in individuals with CF.

Which microRNAs were highlighted in the study?

miR-34a-5p, miR-122-5p, and miR-223-3p were identified as potential biomarkers. MiR-34a-5p and miR-122-5p were elevated in indeterminate glucose tolerance and CFRD, while miR-223-3p showed distinct responses during the OGTT.

Could these microRNA biomarkers eventually lead to earlier and more accurate diagnoses of diabetes in people with cystic fibrosis?